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EVIDENCE-BASED ANSWER 
We found no evidence for changed outcomes from early detection of renal artery stenosis (RAS). 
Treatment of RAS in refractory hypertension modestly improves blood pressure control. There was 
a trend toward improved clinical outcomes but studies were underpowered to demonstrate this 
(strength of recommendation [SOR]: A, based on systematic review of RCTs). 
Treatment of RAS in chronic renal impairment does not appear to improve renal function nor change 
clinical outcomes, but data are conflicting (SOR: A, based on 2 RCTs and multiple cohort studies). 
Subgroups of patients who have recurrent episodes of congestive heart failure or flash pulmonary 
edema exhibit functional improvement following percutaneous transluminal renal angioplasty 
(PTRA) with stent placement. (SOR: C, based on a retrospective cohort study). 
Computed tomography (CT) angiography and magnetic resonance angiography (MRA) are the most 
accurate and cost-effective noninterventional diagnostic modalities for RAS (SOR: A, based on a 
large meta-analysis). 
While revascularization effectively improves patency, the complication rate is high and deaths have 
occurred (SOR: B, based on randomized controlled trials [RCTs]). Patients with worse renal function 
tend to do more poorly (SOR: C, based on retrospective cohort studies). Data are insufficient to 
recommend a method of revascularization (surgical vs PTRA with or without stenting) (SOR: C, 
based on multiple cohort studies). 
CLINICAL COMMENTARY 
When herding hypertensives, treat them all like 
horses, not zebras 
 
Dan  Triezenberg,  MD 
Family Practice Residency, Saint Joseph Regional Medical Center,  South Bend, Ind 
“When you hear hoofbeats, think of horses. You will occasionally see a zebra and very 
rarely a unicorn.” Patients who benefit from physicians looking for and treating 
renovascular hypertension are unicorns, not zebras. A very few patients benefit by 
needing fewer drugs, while a few are harmed by complications of revascularization. No 
benefit in overall mortality, disease specific mortality or vascular morbidity (stroke, heart 
disease) has been demonstrated. So, the take-home message is: When herding 
hypertensives, treat them all like horses—you may stumble across a few zebras, but 
looking for benefit from discovering and treating renovascular hypertension is as fruitful as 
looking for unicorns—a product of imagination, myth, and hope, not based in reality. 
Based on this Clinical Inquiry, I will stop feeling guilty about not searching diligently for 
renovascular causes of “curable hypertension.” 
  EVIDENCE SUMMARY 
“Early” diagnosis of renovascular hypertension is best defined as diagnosis while blood pressure is controlled 
by medications or when renal function remains normal. 
Hypertension. A meta-analysis (3 RCTs, total n=210 patients) examining balloon angioplasty for RAS and 
poorly controlled hypertension showed modest but significant effect on blood pressure control.1 Comparing the 
angioplasty group with medical management, the mean reduction in blood pressure was –7 mm Hg systolic 
(95% confidence interval [CI], –12 to –1) and –3 mm Hg diastolic (95% CI, –6 to –1). Patients treated with 
balloon angioplasty were more likely to use fewer antihypertensive medications (unable to synthesize data for 
quantity) and to have fewer major cardiovascular and renovascular complications (not defined specifically) 
(odds ratio [OR]=0.27; 95% CI, 0.06–1.23; P=.09).1 One cohort study of 150 patients found that stenting 
bilateral (vs unilateral) RAS predicted a more beneficial blood pressure response (OR=4.6; P=.009).2 
Renal impairment. The value of RAS intervention for patients with hypertension and worsening renal function 
is unclear. One RCT of 106 patients with atherosclerotic RAS and serum creatinine (Cr) of <2.3 mg/dL 
compared PTRA with medical therapy of hypertension. By an intentionto-treat analysis, there was no significant 
difference in renal function at 12 months between the groups.3 A nonblinded RCT of 85 patients found no 
change in mortality or renal function with intervention. Three groups were compared: observation of 52 patients 
with unilateral RAS (>50%), intervention on 12 patients with bilateral RAS, and observation of 21 patients with 
bilateral RAS. All groups reported 32% mortality at 2 years. Only 3 of the 27 deaths were directly related to 
renal disease (2 from the observation group with unilateral RAS and one from the intervention group).4 Cohor 
studies, using different measures of renal function, report improvement, stabilization, or worsening following 
intervention.5-7 
Congestive heart failure and flash pulmonary edema. 
Patients who have recurrent episodes of congestive heart 
failure or flash pulmonary edema with severe RAS have 
marked functional improvement following PTRA with 
stenting. One retrospective cohort study (n=39) reported a 
decrease in hospitalizations (from 2.4 ±1.4 per year to 0.3 ±0.7 per year; P<.001) and improvement in New 
York Heart Association heart failure functional classification (2.9 ±0.9 to 1.6 ±0.9).8 
Diagnosis. MRA (sensitivity 99%, specificity 93%) and CT angiography (sensitivity 97%, specificity 95%) are 
the most accurate and cost-effective, based on a large meta-analysis.9 
Complications. Serious or potentially serious complications (ie, bleeding, renal artery injury, need for 
hemodialysis) were seen in 13% to 25% of patients who underwent angioplasty.2,5,7 Combining 3 studies 
(n=632), there were 5 procedurerelated deaths.5,7,10 
Worsened patient survival correlated with Cr >1.7 mg/dL or age >70 (OR=9.96, P<.0001 and OR=3.4, P=.001, 
respectively). Worsened renal survival was present in the same subgroups (OR=7.8, P<.001 and OR=2.7, 
P<.01, respectively).7 
Recommendations from others 
The American Heart Association lists 3 clinical criteria for revascularization: 1) hypertension (accelerated, 
refractory, or malignant), 2) renal salvage, 3) cardiac disturbance syndromes (recurrent “flash” pulmonary 
edema or unstable angina with significant RAS).11 JNC 7 does not recommend looking for RAS unless 
hypertension is uncontrollable.12 
The Society of Nuclear Medicine recommends that only moderate- to high-risk individuals be screened for 
RAS. This guideline clarifies that RAS does not equal renovascular hypertension and that the future “gold 
standard” diagnosis of renovascular hypertension should be the response to successful revascularization.13 
R E F E R E N C E S  
1. Nordmann  AJ, Woo  K, Parkes  R, Logan  AG. Balloon angioplasty or medical 
therapy for hypertensive patients with atherosclerotic renal artery stenosis? A meta-
analysis of randomized controlled trials.  Am J Med 2003;114:44–50. 
2. Zeller  T, Frank  U, Muller  C , et al.  Stent-supported angioplasty of severe 
atherosclerotic renal artery stenosis preserves renal function and improves blood 
pressure control: long-term results from a prospective registry of 456 lesions.  J 
Endovasc Ther 2004;11:95–106. 
3. Van Jaarsveld  BC, Krijnen  P, Pieterman  H , et al.  The effect of balloon 
angioplasty on hypertension in atherosclerotic renalartery stenosis. Dutch Renal 
Artery Stenosis Intervention Cooperative Study Group.  N Engl J 
Med 2000;342:1007–1014. 
FAST TRACK 
Only patients with CHF or flash 
pulmonary edema clearly 
benefit from stenting 
4. Pillay  WR, Kan  Y, Crinnion  J, Wolfe  J. Prospective multicentre study of the 
natural history of atherosclerotic RAS in patients with peripheral vascular disease. 
 Br J Surg 2002;89:737–740. 
5. Rundback  JH, Manoni  T, Rozenblit  GN , et al.  Balloon angioplasty or stent 
placement in patients with azotemic renovascular disease: a retrospective 
comparison of clinical outcomes.  Heart Dis 1999;1:121–125. 
6. Lederman  RJ, Mendelsohn  FO, Santos  R, Phillips  HR, Stack  RS, Crowley  JJ. 
Primary renal artery stenting: characteristics and outcomes after 363 procedures. 
 Am Heart J 2001;142:314–323. 
7. Perkovi  V, Thomson  KR, Becker  GJ. Factors affecting outcome after 
percutaneous renal artery stent insertion.  J Nephrol 2002;15:649–654. 
8. Gray  BH, Olin  JW, Childs  MB, Sullivan  TM, Bacharach  JM. Clinical benefit of 
renal artery angioplasty with stenting for the control of recurrent and refractory 
congestive heart failure.  Vasc Med 2002;7:275–279. 
9. Vasbinder  C, Nelemans  P, Kessels  AGH, Kroon  AA, de Leeuw  PW, van 
Engelshoven  JM. Diagnostic tests for renal artery stenosis in patients suspected of 
having renovascular hypertension: a meta-analysis.  Ann Intern Med 2001;135:401–
411. 
10. Isles  CG, Robertson  S, Hill  D. Management of renovascular disease: a review of 
renal artery stenting in ten studies.  QJM 1999;92:159–167. 
11.  American Heart Association.Rundback  JH, Sacks  D, Kent  KC , et al.  Guidelines 
for the reporting of renal artery revascularization in clinical trials. 
 Circulation 2002;106:1572. 
12. Chobanian  AV, Bakris  GL, Black  HR , et al.  The Seventh Report of the Joint 
National Committee on Prevention, Detection, Evaluation, and Treatment of High 
Blood Pressure: the JNC 7 Report.  JAMA 2003;289:2560–2571. 
13. Taylor  AT  Jr,  Blaufox  MD, Dubovsky  EV , et al.  Procedure guideline for 
diagnosis of renovascular hypertension, 3.0.  Reston,Va: Society of Nuclear 
Medicine; 2003. 
THE JOURNAL OF FAMILY PRACTICE ©2005 Dowden Health Media 
 
